In contrast, RIPK3 inhibitor GSK’872 significantly reduces smoking-induced lung macrophage and epithelial cell death [51,56] and markedly improves COPD-related pathological changes [56]. Here, RIPK3 is linked to chronic obstructive pulmonary disease.